Evotec Past Earnings Performance

Past criteria checks 0/6

Evotec's earnings have been declining at an average annual rate of -44.1%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 16.3% per year.

Key information

-44.1%

Earnings growth rate

-44.3%

EPS growth rate

Life Sciences Industry Growth	26.8%
Revenue growth rate	16.3%
Return on equity	-7.5%
Net Margin	-10.7%
Next Earnings Update	22 May 2024

Recent past performance updates

Recent updates

Evotec SE's (ETR:EVT) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 21

Revenue & Expenses Breakdown
Beta

How Evotec makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XTRA:EVT Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	781	-84	170	69
30 Sep 23	821	-95	174	70
30 Jun 23	798	-103	177	71
31 Mar 23	779	-117	169	74
31 Dec 22	751	-176	156	77
30 Sep 22	698	-180	144	74
30 Jun 22	684	2	126	74
31 Mar 22	650	90	116	72
31 Dec 21	618	216	105	72
30 Sep 21	571	247	90	71
30 Jun 21	541	112	87	70
31 Mar 21	515	42	81	67
31 Dec 20	501	6	77	64
30 Sep 20	485	14	78	63
30 Jun 20	470	35	72	59
31 Mar 20	462	42	68	59
31 Dec 19	446	38	66	58
30 Sep 19	419	61	62	56
30 Jun 19	404	77	60	55
31 Mar 19	398	94	58	45
31 Dec 18	375	84	57	36
30 Sep 18	370	63	54	26
30 Jun 18	338	31	54	19
31 Mar 18	294	20	48	18
31 Dec 17	264	23	42	18
30 Sep 17	215	28	39	18
30 Jun 17	193	35	31	18
31 Mar 17	178	36	29	18
31 Dec 16	165	28	27	18
30 Sep 16	160	18	24	18
30 Jun 16	148	6	25	19
31 Mar 16	144	17	25	19
31 Dec 15	128	17	25	18
30 Sep 15	119	12	24	17
30 Jun 15	104	11	21	15
31 Mar 15	93	-4	19	13
31 Dec 14	89	-7	18	12
30 Sep 14	85	-29	17	11
30 Jun 14	89	-25	17	11
31 Mar 14	86	-27	17	10
31 Dec 13	86	-25	17	10
30 Sep 13	83	-10	16	10
30 Jun 13	82	-4	16	9

Quality Earnings: EVT is currently unprofitable.

Growing Profit Margin: EVT is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: EVT is unprofitable, and losses have increased over the past 5 years at a rate of 44.1% per year.

Accelerating Growth: Unable to compare EVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).

Return on Equity

High ROE: EVT has a negative Return on Equity (-7.49%), as it is currently unprofitable.

Evotec Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Recent updates

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec Se Provides Revenue Guidance for 2022

Consensus forecasts updated

Do Evotec's (ETR:EVT) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

At €36.91, Is It Time To Put Evotec SE (ETR:EVT) On Your Watch List?

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Price target increased to €42.92

Consensus EPS estimates increase to €1.40

Revenue & Expenses Breakdown
Beta